Home › Modalities › Radioligand
Radioligand (6 companies)
| Ticker | Company | Therapeutic areas | Programs | Lead stage | Mkt cap | Programs |
|---|---|---|---|---|---|---|
| AKTS | Aktis Oncology | Oncology | 2 | Phase 1 | $880M | 10 |
| DRTS | Alpha Tau Medical | Oncology | 6 | Phase 2 | $1.27B | 6 |
| BCYC | Bicycle Therapeutics | Oncology | 1 | Phase 2 | $253M | 4 |
| CLRB | Cellectar Biosciences | Oncology | 6 | Phase 2 | $11.8M | 6 |
| IMNM | Immunome | Oncology Rare | 1 | NDA Submitted | $2.13B | 9 |
| CATX | Perspective Therapeutics | Oncology | 4 | Phase 1 | $95.9M | 4 |
No companies match.